----
Current ValuationThe current P/E ratio is -0.21, within the reasonable range, cheaper than 77.78% of the time in the past 1 years, and the industry ranks 60/173, the industry Median -0.92.
-0.208xP/E
$0.73Stock price
$-3.49Earnings per share
-0.208xP/E
Stock price$0.73Earnings per share$-3.49
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.11x
- Typical range
- -0.22x–-0.06x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -11.84x | 141.71% | $12.59B |
GKOSUSGlaukos | -51.97x | 75.37% | $9.77B |
TFXUSTeleflex | -5.14x | 118.39% | $5.30B |
PLSEUSPulse Biosciences | -47.94x | 27.55% | $3.84B |
IRTCUSIRhythm | -252.18x | 70.88% | $3.52B |
BFLYUSButterfly Network | -29.35x | 34.41% | $2.20B |
AXGNUSAxogen | -63.19x | 18.38% | $2.12B |
ASSTUSStrive | -1.97x | 63.23% | $1.92B |
NVCRUSNovocure | -11.43x | 1.23% | $1.70B |
ATECUSAlphatec | -14.98x | 41.67% | $1.65B |
KMTSUSKestra Medical Tech | -10.55x | 0.94% | $1.58B |
DRTSUSAlpha Tau Medical | -14.37x | -- | $1.33B |
TNDMUSTandem Diabetes | -17.70x | 77.60% | $1.12B |
PRCTUSPROCEPT BioRobotics | -9.60x | 3.47% | $1.05B |
IARTUSIntegra LifeSciences | -144.43x | 109.42% | $1.05B |
AORTUSArtivion | -324.84x | 266.67% | $1.04B |
ENOVUSEnovis | -0.93x | 100.97% | $1.02B |
BBNXUSBeta Bionics | -12.72x | 11.66% | $928.08M |
QDELUSQuidelOrtho | -0.88x | 75.33% | $920.28M |
CBLLUSCeribell | -13.74x | 35.15% | $906.87M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
